Goldman Sachs analysts added Insmed to the firm’s Americas Conviction List as part of its monthly update. Goldman has a Buy rating on Insmed with a $103 price target. The firm says Insmed is on the verge of becoming a three-tiered, multi-product, commercial-stage biotech company with an initial focus in rare pulmonary diseases. This inflection point has traditionally led to more predictable earnings and multiple expansion for biotech stocks, the analysts contend.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed price target raised to $85 from $77 at Wells Fargo
- Insmed price target raised to $98 from $75 at TD Cowen
- Insmed backs 2024 global Arikayce revenues view up 15% to $340M-$360M
- Insmed reports Q2 EPS ($1.94), consensus ($1.27)
- Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update
Questions or Comments about the article? Write to editor@tipranks.com